Online Activities

Online Activities

The NLA offers online education and activities including Lipid Academy Online, Lipid Insights Virtual Journal Club, Virtual Patient Center, and NLA Meeting Highlights.

The Emerging Role of EPA & DHA in Atherosclerosis

Did you miss this symposium at our 2018 Scientific Sessions in Las Vegas? You can now view the symposium presentations online while earning free CME/CE credits.

Take Activity

National Lipid Association
Journal Club

The NLA Journal Club is a series of free webinars designed to keep lipidologists up-to-date on the newest topics and techniques in Clinical Lipidology. Each webinar will include a short presentation and focused discussion from one of our senior members on the chosen journal/publication.

View Webinars

Online Lipid Education Activities

Lipid Education Online is a user-friendly, tech-savvy adaptation of the NLA's live training courses. The National Lipid Association's outstanding live courses are reproduced here in a self-paced, mobile-friendly and interactive online learning experience, especially designed to give you all the tools you need to pursue lipidology as a full-fledged lipid specialist or to enhance your existing practice of medicine.

View Courses

NLA Self Assessment Program

The NLA-SAP series is a comprehensive, interactive clinical problem-solving program that validates, strengthens and reinforces your knowledge of the core curriculum of clinical lipidology. The program provides a critical assessment of your strengths and weaknesses to guide you in the selection of additional CME training courses. Program Page

Complex Lipid Management Self Assessment Program

CLM-SAPs provide problem-solving case-based questions that involve common pharmacological issues faced by lipid specialists. Program Page

Complex Lipid Management Self Assessment Program

CLM-SAPs provide problem-solving case-based questions that involve common pharmacological issues faced by lipid specialists. Program Page

Past Meeting Highlights

The NLA takes pride in our speakers, so much so that we've built up a library of clinical lipidology talks, presentations, and case studies from past years. A great benefit of being an NLA member is that you have the ability to watch talks and presentations from our past conferences online. View Presentations

Virtual Patient Center

The NLA is pleased to announce two new Virtual Patient Management Series (vClinic™) program vClinics: Rosa Visit 1 and Rosa Visits 2-3. Virtual Clinic Page

HDL Activity Center

The Translation of HDL Science Curriculum Slide Library consists of 6 (six) interactive slide lecture note modules and 4 interactive case studies that convey the latest evidence and research on HDL and residual risk epidemiology. View Activity

Partnered Activities

The NLA partners with various medical education providers for special online program, satellite programs at meetings and more. The activities, sometimes accredited, are found here.

Managing LDL-C with PCSK9 Inhibitors: Identifying the Patients, Optimizing the Outcomes

LDL-C is a central focus of cardiovascular risk reduction. Prudent use of PCSK9 inhibitors requires identifying patients with elevated LDL-C at increased risk. High-risk patients include ASCVD patients and those with LDL-C > 190 mg/dL without ASCVD. Awareness of evidence with PCSK9 inhibitors, discussions of best use of PCSK9 inhibitors by lipid experts, and cases aim to facilitate treatment of appropriate patients with these drugs to optimize outcomes. In this program, Chair Dr. James Underberg, and Drs. Ty Gluckman, Margo Minissian, Michael Shapiro, and Pam Taub will use these formats to assist lipidologists in patient management with PCSK9 inhibitors.

Activity Page

Combating Residual Risk with Treatment Intensification: Focus on PCSK9 Inhibitors - A Care Team Forum℠

This activity features an engaging video panel discussion with 3 renowned clinical experts and Charles—a patient living with familial hypercholesterolemia (FH). The lively exchange is enhanced with explanatory visuals; direct note-taking capability; interactive questions; and a full in-suit resource library. The panel will delve into topics covering safety/efficacy data for PCSK9 inhibitors (PCSK9-Is), 2018 ACC/AHA guideline updates, and patient selection for treatment intensification with PCSK9-Is. Faculty will examine key matters in patient care, provide illustrative patient case scenarios, pose practical solutions to common issues encountered in clinical practice, and Charles will provide insight into his experience with FH, its treatment, and his interaction with the healthcare system.

Activity Page

Obtaining Authorization for Use of PCSK9 Inhibitors: A Care Team Forum℠

It took a lot of convincing for Charles to get back on medication to help lower his cholesterol—particularly because his mother, who also had high cholesterol, lived to be 100 years old. He was later diagnosed with familial hypercholesterolemia (FH) and started on a PCSK9 inhibitor (PCSK9-I) after failing several statin and non-statin therapies. Within weeks, he found himself both astounded at its efficacy but also its cost. In this interactive roundtable discussion, Charles, his doctor, and 2 other prominent clinical experts gather to deliberate over reimbursement issues surrounding the clinical use of PCSK9-Is and offer practical strategies to facilitate navigating the prior authorization and appeals process.

Activity Page

Cardiovascular Outcome Trials and Expert Consensus Decision Pathways: Interpreting the Evidence with Nonstatin Therapies

The ongoing presentation of evidence from the IMPROVE-IT and FOURIER trials has created a need for lipidologists to be informed of this information which may have a significant impact on their practice. Furthermore, an assessment of the ODYSSEY OUTCOMES trial, and a comparison/contrast of the FOURIER and ODYSSEY OUTCOMES trials are needed to assist lipidologists with clinical decision-making regarding prudent use of PCSK9 inhibitors. Best practice is rapidly evolving with non-statin therapies, necessitating the release of updated recommendations. In this program, Drs. Giugliano, Ballantyne, Brinton, Saseen, and Toth will analyze landmark trials with non-statin therapies and provide recommendations for practice.

Activity Page

Free CME/CE Activity on Emerging Therapeutics in FH

This live symposium held in conjunction with the 2018 NLA Spring Clinical Update will explore and analyze data in specific patient populations in PCSK9 Inhibitor Therapeutics. Expert faculty will give updates on recent PCSK9 inhibitor data and dive into how to optimally apply these therapies into clinical practice. Recent dyslipidemia guidelines will also be reviewed. The panel will discuss how to best improve outcomes for dyslipidemia patients, including those with stroke or at high CV risk.

Activity Page

PCSK9 Inhibitors and CV Risk Reduction

In this two part educational series, experts discuss how Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a promising strategy for decreasing CV risk in patients.

Activity Page

Lipid Management Beyond Statins: Biologic Basis, New Clinical Evidence and Strategies

For clinicians involved in managing dyslipidemia, including lipidologists, cardiologists, endocrinologists, internists, pharmacists, registered nurses, advance practice registered nurses, and associated allied health professionals.

Activity Page

2018 Spring CLU Vox Media Symposium

This program will focus on the evidence with, and use of, non-statin therapies for LDL-C lowering in the settings of primary and secondary prevention.  An interpretation of recently presented and published secondary analyses from cardiovascular outcome trials with non-statin agents will provide lipid specialists with a more comprehensive evaluation of the efficacy and safety of non-statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD).  Users that view this activity will also receive an expert assessment of non-statin therapy for primary prevention.  Four interactive challenging cases for lipid specialists with “real-world” patients will enable faculty members to describe best management strategies.

Activity Page

Update on Hypertriglyceridemia: Clinical Relevance and Treatment Recommendations

What are the causes and risks of high triglycerides? What are the key lifestyle and pharmacologic strategies available to manage patients? View this free online program to learn more and claim 1.0 AMA PRA Category 1 Credit™.

Activity Page
Average: 4.5 (2 votes)
Publish Date: 
Friday, January 1, 2016 - 01:45

This page was last updated: Jun 08, 2019

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service